Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Insight Genetics and National Cancer Institute Collaborate to Develop New Technologies for Clinical Trials

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
Insight Genetics has developed a diagnostic test that can more accurately determine if certain lung cancer patients will respond to targeted therapies.

The CADP is an initiative of NCI’s Division of Cancer Treatment and Diagnosis, and aims to move promising assays from the research lab into clinical trials.

Insight Genetics’ Insight ALK Screen™ offers comprehensive data that informs a physician if a patient’s cancer is associated with anaplastic lymphoma kinase (ALK) and may respond to ALK-inhibitor therapies, an emerging class of cancer treatments. ALK fusions and mutations have been shown to be a contributing cause in approximately 5-10 percent of lung cancers.
 
"As cancer treatment becomes increasingly targeted at the molecular level, the development of advanced diagnostics that can inform cancer diagnosis and therapy selection will be vital," said Christopher Callaghan, President and COO of Insight Genetics. "Assays like our Insight ALK Screen are important advancements in this evolving cancer landscape. We are extremely gratified to further this field and continue our relationship with NCI by participating in the CADP."

Insight ALK Screen is inexpensive, highly sensitive and well suited to handle larger numbers of specimens than the ALK detection methods currently available. The PCR-based test will reduce the false-negative call frequency of ALK status in tumors, which means more patients who may benefit from ALK inhibitor therapies will receive these targeted treatments. In addition, Insight ALK Screen provides rapid, unambiguous identification of the complete spectrum of oncogenic ALK fusion mutations unachievable by more conventional PCR strategies. Its ease of use and rapid turnaround time will decrease the time in which physicians and their patients receive information.
 
NCI—through the CADP—will support Insight Genetics by providing services of two CLIA-certified labs that will further validate the assay, access to clinical samples, subject matter expertise, and statistical consultation. This collaboration is the continuation of a successful relationship between NCI and Insight Genetics. In the last three years the molecular diagnostics company has been awarded four contracts from NCI for the development of companion diagnostics.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Insight Genetics Announces Promotions for Two Team Members
Kasey Lawrence has been named Senior Technology Specialist, and Tyler Nielsen has been appointed Research Scientist.
Thursday, August 21, 2014
Insight Genetics and Vanderbilt-Ingram Cancer Center Partner
Research collaboration includes exclusive licensing agreement to commercialize a new genetic test that will improve treatment selection for breast cancer patients with poor prognosis.
Wednesday, March 05, 2014
Insight Genetics Awarded NCI Contract
Company receives Phase II Award to continue development of a companion diagnostic test for drugs targeting anaplastic lymphoma kinase.
Tuesday, January 07, 2014
Insight Genetics Launches Insight Molecular Labs
CLIA-certified laboratory offers diagnostic tests that identify specific cancer biomarkers.
Friday, December 13, 2013
Insight Genetics Promotes Four
Molecular diagnostics company builds expertise and depth in research, application and commercial development of companion diagnostics to improve cancer care.
Wednesday, February 13, 2013
Insight Genetics Awarded Qualifying Therapeutic Discovery Program Grant
Diagnostics Company Receives Funds to Advance Cancer Care.
Wednesday, November 17, 2010
Scientific News
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
Cheap Diagnostics with a Portable "Paper Machine"
Scientists have developed a cheap, portable system for point of care diagnostics for a range of infectious diseases, genetic conditions and cancer.
New Variant of Streptococcal Bacteria
Scientists have discovered a new variant of streptococcal bacteria that has contributed to a rise in disease cases in the UK over the last 17 years.
New Insights into “Antenna” of Human Cells
Scientists from the University of Leeds have uncovered the most comprehensive list yet of genes implicated in a group of common inherited diseases.
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Sperm RNA Test May Improve Evaluation of Male Infertility
To help resolve uncertainty—and guide prospective parents to the right fertility treatments—scientists propose the use of a new kind of fertility test. It involves examining sperm RNA by means of next-generation sequencing.
Optical 'Dog's Nose' Developed to Detect Cancer, Other Diseases
Researchers are using optical spectroscopy to develop a quick, non-invasive “breath test” they believe will have the potential to screen for a variety of diseases, including diabetes, infections and cancers.
Ebola Assays Compared in Head-to-Head Analysis
A newly published study has attempted to rigorously evaluate a few of the assays recently granted Emergency Use Authorization by the US Food and Drug Administration to test for Ebola Zaire virus.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!